Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy. (14th October 2022)

• Record Type: Journal Article
• Authors: Riebensahm, Carlotta; Berzigotti, Annalisa; Surial, Bernard; Günthard, Huldrych F; Tarr, Philip E; Furrer, Hansjakob; Rauch, Andri; Wandeler, Gilles
• Is Part Of: Open forum infectious diseases. Volume 9:Number 11(2022)
• Publication Date: 2022-10-14
• Subjects: antiretroviral therapy -- liver steatosis -- metabolic-associated fatty liver disease -- metabolic comorbidities -- people with HIV; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac538
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Given the impact of new antiretroviral drugs on weight and metabolic parameters, their potential contribution to the development of liver steatosis is of concern. We investigated the determinants of liver steatosis in patients on antiretroviral therapy (ART) in the Swiss HIV Cohort Study (SHCS). Methods: Between 2019 and 2021, we measured liver stiffness and controlled attenuation parameter (CAP) using transient elastography in consecutive SHCS participants at Bern University Hospital. Individuals with viral hepatitis coinfection and pregnant women were excluded. We used multivariable logistic regression to explore factors associated with steatosis. Results: Of 416 participants, 113 (27.2%) were female, median age was 51 years (interquartile range [IQR], 43–59), 305 (73.3%) were of European origin, and 212 (51.0%) were overweight/obese (body mass index [BMI] ≥25 kg/m 2 ). Liver steatosis (CAP ≥248 dB/m) was present in 212 (51.0%) participants, 11 (5.2%) of whom had significant fibrosis or cirrhosis. One hundred seventy-nine (43.0%) met the criteria for metabolic-associated fatty liver disease (MAFLD). Among 64 individuals with a BMI <25 kg/m 2 and liver steatosis, 31 (48.4%) had MAFLD. In multivariable analyses, BMI ≥25 kg/m 2 (adjusted odds ratio, 5.76; 95% confidence interval, 3.57–9.29), age ≥50 years (1.88, 1.14–3.09), European origin (3.16, 1.69–5.89), and current use of tenofovir alafenamide (1.70, 1.08–2.69) were associated with liver steatosis. Exposure to integrase inhibitors was not associated with liver steatosis (0.83, 0.51–1.37). Conclusions: Our findings suggest a high prevalence of liver steatosis among people with HIV (PWH) on ART in Switzerland. In addition to established risk factors, the use of tenofovir alafenamide was associated with hepatic steatosis. Abstract : We found a high prevalence of liver steatosis among people with HIV on antiretroviral therapy in Switzerland. In addition to well known risk factors such as age, ethnicity, and obesity, the use of tenofovir alafenamide was associated with hepatic steatosis.